Bedaquiline as a potential agent in the treatment of Mycobacterium abscessus infections Source: Eur Respir J, 49 (5) 1700083; 10.1183/13993003.00083-2017 Year: 2017
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis Year: 2020
Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021 Year: 2022
Bedaquiline as a potential agent in the treatment of M. intracellulare and M. avium infections Source: Eur Respir J , 49 (3) 1601969; DOI: 10.1183/13993003.01969-2016 Year: 2017
Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria Year: 2018
Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019 Year: 2019
Importance of identifying Mycobacterium bovis as a causative agent of human tuberculosis Source: Eur Respir J 2010; 35: 692-694 Year: 2010
In vitro susceptibility testing of bedaquiline against mycobacteria avium-intracellulare complex Source: Virtual Congress 2020 – Aspergillosis and chronic lung infections Year: 2020
Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients Source: Eur Respir J 2013; 41: 1101-1106 Year: 2013
Treatment of refractory mycobacterium avium complex lung disease with a moxifloxacin-containing regimen Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013
Combined chemotherapy in Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: Suppl. 49, 657s Year: 2005
Clinical and laboratory features of Mycobacterium avium complex infection in comparison with infection, caused by Mycobacterium tuberculosis, in HIV-infected patients Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Emerging untreatable non-tuberculous pulmonary disease due to Mycobacterium abscessus Source: Eur Respir J 2004; 24: Suppl. 48, 415s Year: 2004
Pulmonary diseases caused by non-tuberculous mycobacteria Source: Eur Respir Mon 2012; 58: 25-37 Year: 2012
Detection of Mycobacterium tuberculosis in children during complex antimycobacterial therapy Source: Annual Congress 2009 - Genetics of lung diseases Year: 2009
The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017 Year: 2017
Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease Source: International Congress 2019 – Complex respiratory infections in clinical practice Year: 2019
Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019 Year: 2020
Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease Source: Eur Respir J 2009; 33: 148-152 Year: 2009
Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease Source: Eur Respir J 2005; 26: 1092-1096 Year: 2005